Vera Therapeutics

Vera Therapeutics, Inc. is a clinical stage biotechnical company that engages in the development and commercialization of transformative treatments for immunological diseases. Its primary product, atacicept, is a fusion protein self-administered as a subcutaneous injection that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.

Chinook Therapeutics

Novartis

Travere Therapeutics

In light of a Novartis NVS, -0.94% deal to acquire Chinook Therapeutics Inc. KDNY, +58.09%, which is developing treatments for a rare kidney disease, two other companies focused on the same disease look even more attractive, analysts said Monday.

Novartis deal for Chinook makes kidney-treatment competitors more attractive, analysts say

Vera Therapeutics is a clinical-stage biotech. One of Vera's competitors in kidney therapies just agreed to a buyout offer from Novartis.

Why Shares of Vera Therapeutics Are Soaring Monday

Clean Energy Fuels

Kroger

Northern Oil and Gas

Palo Alto Networks

Pure Storage

Rent the Runway

Peruse the Internet and you'll eventually see opinions deriding top analyst recommended stocks as nothing but a clown show. Sure enough, many experts do get it wrong because let's face it: if someone could truly predict the market consistently even 70% of the time, they wouldn't be on TV.

7 Stocks That Wall Street Analysts Are Loving in June

BRISBANE, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will participate in the 44th Annual Goldman Sachs Global Healthcare Conference, which is taking place in Dana Point, CA from June 12 – 15, 2023. Marshall Fordyce, Founder and Chief Executive Officer, and Sean Grant, Chief Financial Officer will be participating in a fireside chat during the conference.

Vera Therapeutics to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference

Pivotal Phase 3 Trial for Atacicept in IgA Nephropathy Initiated Today Late-breaking results of ORIGIN Phase 2b trial supporting further evaluation of atacicept 150 mg as a potential disease-modifying treatment for IgAN will be presented at 60th European Renal Association (ERA) Congress BRISBANE, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced initiation of the pivotal Phase 3 clinical trial (ORIGIN 3) of atacicept for the treatment of IgA nephropathy (IgAN).

Vera Therapeutics Initiates Pivotal Phase 3 (ORIGIN 3) Clinical Trial of Atacicept for the Treatment of IgA Nephropathy (IgAN)

Vera Therapeutics (VERA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Vera Therapeutics (VERA) Ahead of Earnings?

BRISBANE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business updates and financial results for the first quarter ended March 31, 2023. “We continue to build momentum in the clinical development of our lead product candidate, atacicept, for the treatment of IgAN, as we prepare to initiate the pivotal Phase 3 study in the second quarter of 2023,” said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. “We are pleased to announce that the 36-week results from the Phase 2b ORIGIN study of atacicept were selected as a late breaking clinical trial for presentation at the 60th ERA Congress. These data follow the positive efficacy and safety data from the ORIGIN study presented in the first quarter of 2023, which show atacicept's ability to substantially reduce proteinuria. We look forward to continuing to execute on our program and atacicept's potential as a transformative, best-in-disease therapy for patients with IgAN.” First Quarter and Recent Business Highlights

Vera Therapeutics Provides Business Update and Reports First Quarter Financial Results

American Assets

AbbVie

Byline Bancorp

Coastal Financial Corp

Clear Channel Outdoor Holdings

Compass Minerals

Enovix Corporation

Heartland Express

iHeartMedia

JELD-WEN Hld

Mineralys Therapeutics Inc

OPKO Health

PacWest Bancorp

Precigen

Paramount Group

Purple Innovation

B. Riley Financial

Cassava Sciences Inc

Summit Therapeutics

SPDR S&P 500 ETF Trust

Triumph Financial Inc

LendingTree

Strong Small-Cap Insider Buys: Q1 2023

BRISBANE, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights for the fourth quarter and financial results for the full year ended December 31, 2022.

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

NEW YORK , Feb. 6, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vera Therapeutics, Inc. ("Vera" or the "Company") (NASDAQ: VERA).  Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vera Therapeutics, Inc. - VERA

BRISBANE, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has commenced a public offering, subject to market and other conditions, to issue and sell $75.0 million of shares of its Class A common stock. All of the shares are being offered by Vera.

Vera Therapeutics Announces Commencement of Public Offering of Class A Common Stock

Vera continuing plans to rapidly advance atacicept into a pivotal Phase 3 trial in 1H 2023; full data to be presented at upcoming medical congresses

Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy; Patients in the 150 mg Dose Group Achieved a Delta of 48% Versus Placebo in Mean Reduction in Proteinuria

ATHLONE, Ireland--( BUSINESS WIRE )--Innocoll Holdings Ltd. (“IHL”), a global biotech pharmaceutical company and portfolio business of Gurnet Point Capital (“GPC”), today announced the appointment of Kimball Hall, a seasoned commercial operations executive, as President and Chief Executive Officer. As part of this appointment, Kimball will also serve as Chief Executive Officer of IHL's two subsidiaries: Syntacoll GmbH (“Syntacoll”), a contract development and manufacturing organization (“CDMO”) specializing in collagen-based technology platforms, and Innocoll Biotherapeutics Inc. (“Innocoll”), a global biotech company focusing on delivering non-opioid alternatives for postsurgical pain management.

Innocoll Holdings Ltd. Appoints Kimball Hall as Chief Executive Officer

Vera's stock gained a noteworthy 49% this week.

Why Vera Therapeutics Stock Bolted Higher This Week

Cutera

Baxter

Tricida Inc

Third Harmonic Bio Inc

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

5 Cheapest Health Care Stocks You Should Think About - Baxter Intl (NYSE:BAX), Cutera (NASDAQ:CUTR)

LOS ANGELES--( BUSINESS WIRE )--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Vera Therapeutics, Inc. (“Vera” or “the Company”) (NASDAQ: VERA) for violations of the securities laws.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Vera Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Fate Therapeutics

Graphite Bio

Century Therapeutics

Top 5 Health Care Stocks That May Surge - Graphite Bio (NASDAQ:GRPH), Fate Therapeutics (NASDAQ:FATE)

VERA posts positive top-line data from the phase IIb ORIGIN study evaluating atacicept for the treatment of IgA nephropathy.

VERA Dips Despite Positive Data From IgA Nephropathy Study

Geron

The binary nature of biotech investing is making itself obvious from recent study results.

These 2 Nasdaq Biotechs Are Making Big Moves Wednesday

A kidney disease treatment from Vera lagged rivals from Chinook and Otsuka, analysts said Wednesday as the biotech stock plummeted. The post Why Vera Stock Crashed 60% On Its 'Positive' Kidney Drug Update — And Chinook Popped appeared first on Investor's Business Daily.

Why Vera Stock Crashed 60% On Its 'Positive' Kidney Drug Update — And Chinook Popped

Atacicept met primary endpoint at 24 weeks, and also achieved statistical significance in the 150 mg dose group with a 33% mean reduction in proteinuria from baseline, with available data showing trend towards further reductions in proteinuria at week 36

Vera Therapeutics Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

BRISBANE, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present at the 41st Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 9 – 12, 2023. The management team will also participate in one-on-one investor meetings.

Vera Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference

BRISBANE, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present and participate in one-on-one meetings at the following investor conferences, as detailed below:

Vera Therapeutics to Present at Upcoming Investor Conferences

Dr. Barratt will discuss disease burden and pathogenesis of IgAN, a common cause of kidney failure and a high unmet medical need globally

Vera Therapeutics to Host Key Opinion Webinar on Targeting the Source of IgA Nephropathy (IgAN) Featuring Jonathan Barratt, Ph.D., FRCP

BRISBANE, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the quarter ended September 30, 2022.

Vera Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results

News for Vera Therapeutics Stock (VERA)